© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
oral SAM-competitive PRMT5 inhibitor
Ph. I candidate for solid tumors (adv. or met.)
SBDD utilizing PRMT5:MEP50 w/ A9145C
Molecular Cancer Therapy
10. The Pfizer SAM-competitive PRMT5 inhibitor, PF-06939999 is a Ph. I clinical candidate in dose escalation in solid tumors. Ph. I data has been reported showing signs of early efficacy with cytopenias as…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.